NRF1 promotes m6A modification and IGF2BP2‐dependent stability of GLRX mRNA by increasing the expression of METTL3 and leads to the increase of GLRX expression, thus alleviating motor dysfunction and dopamine neuron degeneration in Parkinson's disease mice. Here, GLRX is linked to Parkinson disease.